Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Wolf

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Journal of Toxicologic Pathology|July 8, 2026
INHAND: Non-proliferative and proliferative lesions of fish - Chapter 14. Fish special sensesWes Baumgartner, Ute Bach, James Baily, et al.
Journal of Toxicologic Pathology|July 8, 2026
INHAND: Non-proliferative and proliferative lesions of fish - Chapter 13. Fish soft tissuesWes Baumgartner, Ute Bach, James Baily, et al.
JMIR Formative Research|January 18, 2022
Digital Life Coaching During Stem Cell Transplantation: Development and Usability StudyRahul Banerjee, Chiung-Yu Huang, Lisa Dunn, et al.
Oral Oncology|June 2, 2024
Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancerRebecca Krc, William Mendes, Jason Molitoris, et al.
Cellular and Molecular Life Sciences : CMLS|January 11, 2026
HOXC6 overexpression stimulates cell migration and correlates with poor prognosis in head and neck squamous cell carcinomaSubhendu Roy Choudhury, Ishita Gupta, Ian Mills, et al.
British Journal of Haematology|November 19, 2009
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myelomaWilliam I Bensinger, Sundar Jagannath, Robert Vescio, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Plos One|September 1, 2020
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurementsMaria-Teresa Cedena, Estela Martin-Clavero, Sandy Wong, et al.
Head & Neck|January 31, 2012
Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinomaCaroline J Voskens, Duane Sewell, Ronna Hertzano, et al.
Blood Advances|May 21, 2020
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myelomaRafael Alonso, María-Teresa Cedena, Sandy Wong, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Journal of Toxicologic Pathology|July 8, 2026
INHAND: Non-proliferative and proliferative lesions of fish - Chapter 14. Fish special sensesWes Baumgartner, Ute Bach, James Baily, et al.
Journal of Toxicologic Pathology|July 8, 2026
INHAND: Non-proliferative and proliferative lesions of fish - Chapter 13. Fish soft tissuesWes Baumgartner, Ute Bach, James Baily, et al.
JMIR Formative Research|January 18, 2022
Digital Life Coaching During Stem Cell Transplantation: Development and Usability StudyRahul Banerjee, Chiung-Yu Huang, Lisa Dunn, et al.
Oral Oncology|June 2, 2024
Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancerRebecca Krc, William Mendes, Jason Molitoris, et al.
Cellular and Molecular Life Sciences : CMLS|January 11, 2026
HOXC6 overexpression stimulates cell migration and correlates with poor prognosis in head and neck squamous cell carcinomaSubhendu Roy Choudhury, Ishita Gupta, Ian Mills, et al.
British Journal of Haematology|November 19, 2009
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myelomaWilliam I Bensinger, Sundar Jagannath, Robert Vescio, et al.
Blood|March 17, 2012
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myelomaShaji Kumar, Ian Flinn, Paul G Richardson, et al.
Plos One|September 1, 2020
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurementsMaria-Teresa Cedena, Estela Martin-Clavero, Sandy Wong, et al.
Head & Neck|January 31, 2012
Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinomaCaroline J Voskens, Duane Sewell, Ronna Hertzano, et al.
Blood Advances|May 21, 2020
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myelomaRafael Alonso, María-Teresa Cedena, Sandy Wong, et al.
Pageof 8